ATSDR
Environmental Medicine | CSEM | GREM | Continuing Education | Patient Education | PEHT | Community
Section Contents
Learning Objectives
Nicotinic Receptor Function
Molecular Physiology
Structure and Physiology
Receptor Location
Clinical Findings
Nicotinic Mnemonic
Key Points
Progress Check
 
Case Contents
Table of Contents
Cover Page
How to Use the Course
Initial Check
Mass Casualty Events
Cholinesterase Inhibitors
Pathological Conditions
Cholinergic Toxidrome
Muscarinic Receptors
Nicotinic/Muscarinic Mixture
Signs and Symptoms
Laboratory Tests
Differential Diagnosis
Pediatric Cases
Exposure History
RBC & Serum Tests
Inhibitors & Byproducts
Management Strategies
Secondary Exposure
Supportive Care
First-Line Medications
Medications: Atropine
Medications: Pralidoxime
Medications: Diazepam
Antidote Stocking
Deprecated Treatments
Medico-Legal Issues
Intermediate Syndrome
Delayed Neuropathy
Chronic Neurotoxicity
Other Issues
Posttest
Literature Cited
 
Related Documents
MMG: Nerve Agents
ToxFAQs™: Nerve Agents
 
Environmental Medicine
CSEM
GREM
PEHT
Continuing Education
Online Registration
Patient Education
Community Education
 
ATSDR Resources
ATSDR en Español
Case Studies (CSEM)
Exposure Pathways
HazDat Database
Health Assessments
Health Statements
Interaction Profiles
Interactive Learning
Managing Incidents
Medical Guidelines
Minimal Risk Levels
Priority List
ToxFAQs™
ToxFAQs™ CABS
Toxicological Profiles
Toxicology Curriculum
 
External Resources
CDC
eLCOSH
EPA
Healthfinder®
Medline Plus
NCEH
NIEHS
NIOSH
OSHA

Agency for Toxic Substances and Disease Registry 
Case Studies in Environmental Medicine (CSEM) 

Cholinesterase Inhibitors
Including Insecticides and Chemical Warfare Nerve Agents
Part 4: The Cholinergic Toxidrome
Section 2: Nicotinic Acetylcholine Receptors

Learning Objectives

Upon completion of this section, you will be able to:

  • Describe the key function of nicotinic receptors.
  • Describe where nicotinic receptors are found.
  • Identify the key physiological effects that result from stimulation of nicotinic receptors by excessive amounts of acetylcholine.

Key Function of Nicotinic Receptors

The key function of nicotinic receptor proteins is to trigger rapid neural and neuromuscular transmissions.

For those interested in learning about the molecular physiology of nicotinic receptors, the subject is discussed as optional reading below.

Molecular Physiology of Nicotinic Receptors (Chemical-Gated Na+ Channels) (Optional Reading)

Physiology of nicotinic receptors

The nicotinic receptors are cylindrically-shaped proteins imbedded in synaptic walls that act as chemically-controlled sodium channels (also called ligand-gated sodium channels) that penetrate through the cell walls of post-synaptic nerves and myocytes at the skeletal neuromuscular junctions. (Guyton and Hall 2006) (See Figure 6 below) (Smooth muscle contraction is controlled by muscarinic receptors, which are different and will be discussed later.)

When the neurotransmitter, acetylcholine, attaches to the portion of the nicotinic receptor outside of the cell wall, it induces a conformational change that selectively opens up the channel to sodium ions. The resulting influx of positively charged sodium then triggers membrane depolarization. Depolarization is followed by the opening of other transmembrane channels that selectively allow the flow of K+ ions into the cell. This results in repolarization. The period between depolarization and repolarization is called the refractory period. This is because during this time the cell cannot be depolarized by an additional stimulus. (Guyton and Hall 2006)

The channel opening in the nicotinic receptor normally lasts less than a millisecond because the enzyme, cholinesterase, rapidly breaks down acetylcholine. Since channel opening is triggered by the attachment of a chemical (or “ligand”) --- in this case, acetylcholine --- these channels are called chemical- or ligand-gated channels. As long as the chemical (in this case acetylcholine) is attached, the channel stays open. (Guyton and Hall 2006)

Toxic levels of cholinesterase inhibitors prevent the breakdown of acetylcholine. As a result, the chemical-gated nicotinic receptor Na+ channels are held in the open position, and a constant state of depolarization occurs. This results in a prolonged refractory period, during which no further transmission can occur. This is referred to as a depolarization block, and is similar to the depolarization block caused by succinylcholine. (Taylor 2001)

Clinical Picture Due to Nicotinic Effects of Cholinesterase Inhibitors

These events help to explain why the initial phase of toxicity is manifested by over-stimulation (characterized by myoclonic jerks, fasciculations and muscle spasms) followed by weakness progressing to paralysis.

Molecular Structure and Physiology of the Nicotinic Receptor (Optional Reading)

Nicotinic Receptor

Figure 6. The nicotinic receptor. Figure modified with permission from: Guyton AC, Hall JE: Textbook of Medical Physiology (2006) Elsevier Saunders, Philadelphia. P.87. Used with permission.

Locations of Nicotinic Receptors

Nicotinic receptors are located in the (See also Figure 6)

  • Skeletal neuromuscular junctions.
  • Sympathetic and parasympathetic nervous system.
  • Autonomic ganglia.
  • Central nervous system.

Clinical Findings Due to Nicotinic Stimulation from Cholinesterase Inhibitors

Clinical findings are related to effects on the:

  • Neuromuscular junctions of skeletal muscles.
    • Fasciculations and myotonic jerks, followed by weakness and paralysis.
  • Sympathetic nervous system (due to ganglionic stimulation of the adrenal gland). (See Figure 5)
    • Hyperglycemia, glycosuria, ketosis. (Schenker, Louie et al. 1998; Clark 2002)
    • Hypertension. (Erdman 2004)
    • Leukocytosis with a left shift. (Schenker, Louie et al. 1998; Tareg, B et al. 2001)
    • Mydriasis (pupillary dilation) (Erdman 2004) (in up to 13% of the cases (Clark 2002)).
    • Sweating.
    • Tachycardia, tachydysrhythmias. (Erdman 2004)
    • Urinary retention. (Clark 2002)

Nicotinic Mnemonic

The table below shows a mnemonic for remembering the nicotinic signs of cholinesterase inhibitor toxicity

Monday

Mydriasis (pupillary dilation)

Tuesday

Tachycardia

Wednesday

Weakness

Thursday

Hypertension

Friday

Fasciculations

Key Points

  • A key function of nicotinic receptors is to trigger rapid neural and neuromuscular transmission.
  • Nicotinic receptors are found in:
    • The somatic nervous system (neuromuscular junctions in skeletal muscles).
    • The sympathetic and parasympathetic nervous system (autonomic ganglia).
    • The central nervous system (Discussed later).
  • Peripheral nervous system clinical findings include
    • Fasciculations and myotonic jerks (central nervous system effects are discussed later).
    • Weakness and paralysis.
    • Sweating.
    • Mydriasis (pupillary dilation) (in up to 13% of the cases).
    • Tachycardia, tachydysrhythmias.
    • Hypertension.
    • Hyperglycemia, glycosuria, ketosis.
    • Leukocytosis with a left shift.

Progress Check

12. Nicotinic receptors: (Choose ALL correct answers)

A. Trigger rapid neural transmission.
B. Trigger rapid neuromuscular transmission.
C. Become stimulated then paralyzed by toxic levels of acetylcholine.
D. Are found only in the autonomic nervous system.
E. None of the above.

Answer:

To review relevant content, see Key Functions of Nicotinic Receptors in this section.

13. Over stimulation of nicotinic receptors can cause: (Choose ALL correct answers)

A. Tachycardia.
B. Fasciculations.
C. Mydriasis (pupillary dilation).
D. Leucopenia.
E. None of the above.

Answer:

To review relevant content, see Clinical Findings Due to Nicotinic Stimulation from Cholinesterase Inhibitors in this section.

14. Nicotinic receptors are found in which of the following locations: (Choose ONE best answer)

A. Sympathetic nervous system.
B. Parasympathetic nervous system.
C. Central nervous system.
D. All of the above.
E. None of the above.

Answer:

To review relevant content, see Locations of Nicotinic Receptors in this section.

Previous Section

Next Section

Revised 2007-10-16.